My finance view

The complex prescription for successful health care investing usually includes the careful consideration of drug pipelines, current-product sales, patent expirations, potential mergers and stock dividends.

Add to that list in 2010 an untested ingredient called health care reform.

"Institutional investors don’t want to see big headlines about the health care industry that they weren’t able to predict," said Les Funtleyder, health care strategist for Miller Tabak & Co. in New York. "So they’re currently operating on the fear of increased regulation or pricing pressures."

If you’re in any way optimistic that the outcome of health care reform won’t be bad for drug companies, the current fears mean that health care stock prices will never be more reasonable than they are now. Prices are depressed and the dividends solid.

"Once we know what the reform will look like in detail we can then move forward," believes Linda Bannister, health care analyst for Edward Jones in St. Louis. "Managed care is the most at risk from health care reform, and then the risk declines from there."

Beyond the potential negatives of reform on drug stocks there may be some long-term positives.

"If 30 million people who didn’t have health insurance were to have it, imagine what that does for a pharmaceutical company," said James Molloy, pharmaceutical analyst for Caris & Co. in Boston. "The plus side of drugs is that most people with insurance never pay full price, but instead pay a co-pay, and you can imagine what kind of car everyone would drive if they had a co-pay for their gas."

While awaiting a clear prognosis on reform, investors must fall back on traditional considerations that tend to favor big pharma that keeps growing bigger.

Merck & Co., whose stock is flat this year after a 25 percent gain last year, is recommended by Bannister and Funtleyder because its strong product pipeline means it won’t require the endless cutting of costs to be profitable. It faces loss of patents on several key drugs in coming years and fierce competition, yet its financial health is strong and its research excellent.

Merck’s launches of diabetes drug Januvia, papillomavirus vaccine Gardasil and HIV drug Isentress have all been successes, while its acquisition of Schering-Plough could result in $3.5 billion in annual cost-saving synergies by 2012. More than half of Merck’s sales are outside the U.S.

Johnson & Johnson, its stock down slightly this year after last year’s 11 percent rise, has suffered through a period of patent expirations, but Bannister believes its drug pipeline coupled with continued efficiencies should accelerate its growth. It benefits from being the world’s largest and most diverse health-care company, with the top or number-two leadership position in 70 percent of its products.

"I cover mostly smaller names of the world and try to find those with downside protection in the form of some core value," said Molloy.

Warner Chilcott Plc, whose stock is down 8 percent this year after last year’s 96 percent gain, is Molloy’s top pick in part because it has massive cash flow. This marketer of women’s health and dermatology products recently purchased Procter & Gamble’s prescription drug business. Its product mix includes hormonal oral contraceptives and hormone therapy products for menopausal symptoms, as well as topical products for psoriasis and an antibiotic for acne.

The other Molloy favorite is Endo Pharmaceutical Holdings Inc., up 10 percent this year after last year’s 21 percent decline. It is a specialty drug company in pain management whose flagship product is the Lidoderm adhesive patch for post-shingle pain. The company, which cross-sells many of its pain-related products, last year acquired Indevus Pharmaceuticals, which specializes in urology and endocrinology.

"My biggest consideration is whether the good news or bad news is factored into the stock price," explained Molloy. "I also ask whether its primary drug has to be a $1 billion drug for the company’s stock price to go higher."

Novartis AG and Bristol Myers Squibb Co. are Funtleyder’s other favorites. Though he says "no one is firing on all cylinders right now," there is little downside, they offer solid dividends and their upside is the enormous potential of their drug pipelines.

Mergers can come fast and furious among drug companies, but is an unpredictable trend that none of the experts expect will take place soon.

"Pharma has been a consolidating industry ever since it was an industry," said Funtleyder, noting that patent expirations and slowing sales drove the most recent mergers and innovation may someday drive the next go-around. "Consolidation happens in waves and last year was a pretty big wave, so we think there will be a break for a couple of years before we see the next wave of consolidation."

Other Bannister choices include Eli Lilly & Co., Pfizer Inc. and Abbott Laboratories.

"If a company like Lilly is unable to execute its pipeline, then at some point it is going to have to make a sizeable acquisition or it will potentially be acquired," concluded Bannister, who considers investment in Lilly a three- to five-year story. "Yet most of these companies’ strategies are licensing deals or small ‘tuck-in’ acquisitions, so I’m not betting on a new wave of industry consolidation."

Source

Compare health insurance plans and insurance rates on family and individual health insurance. Free health quotes and more.

St. Louis University will tap into the large pool of laid-off Pfizer scientists to launch a new research center focused on discovering drugs to treat medical problems in the developing world.

SLU has committed $5 million over the next two years to fund the Center for World Health & Medicine, which will launch in July, Raymond Tait, SLU’s vice president for research, said Wednesday. The school initially plans to hire a dozen soon-to-be former Pfizer researchers.

In November, Pfizer announced it would lay off 600 of its 1,000 employees in St. Louis, part of a 15 percent reduction of the drugmaker’s global work force. The reductions followed Pfizer’s $68 billion acquisition of the drugmaker Wyeth. Pfizer’s main research campus in the area is located in Chesterfield.

SLU began discussions in early December to figure out ways to keep some of those scientists in St. Louis. In a time of strained university resources, this reflects SLU’s commitment to the region, Tait said.

"St. Louis U. worked with uncharacteristic speed," he said. "The initial reaction was a form of horror to think about the impact of (the layoffs) on the St. Louis region. After we had a chance to digest it, we then thought, ‘Gee, this also provides us with an important opportunity that could be transformative for research at St. Louis U.’"

This is a somewhat unusual venture, in that universities have not typically delved into the realm of drug discovery, Tait acknowledged.

"We’re not going to compete with Pfizer and Wyeth," he said. "We’re not going after blockbuster drugs."

Rather, the appealing part of this idea was that the school could follow its Jesuit mission by helping underserved populations, he said.

Steve Johnson, senior vice president of the St. Louis Regional Chamber and Growth Association, said SLU’s move is a small but important step in the right direction if St. Louis hopes to plug the leakage of high-skilled workers to other areas.

There are between 1,700 and 2,000 laid-off scientists and skilled technical workers in the region right now, Johnson said. Keeping them, and their skills, in St. Louis is becoming an increasingly high priority, he said.

"That represents a tremendous amount of talent," Johnson said payday advance. "You don’t want to dehumanize people, but those are marketable assets for the region."

They are the kind of assets that can help lure other big medical and technology firms here, or that can seed startups, or that, as in this case, can help launch research groups at local universities.

"We applaud (SLU’s effort)," Johnson said. "And we’ll be digging into this whole issue and look at what other regions are doing."

SLU still has to hash out many of the details about the new center — such as whom exactly it will hire, where it will be housed, and what areas it will focus on.

"This is still a work in progress," Tait said. "Give us another couple of months where we can flesh out who will be working with us."

While many of the scientists have already vacated their laboratories, they are still under contract with Pfizer, Tait said. So SLU has not yet officially hired anyone, but it has spoken with several people who are very interested in the new center, he said.

Targeting childhood diarrhea is one area that some scientists have expressed a special interest in, he added.

Tait said he hopes the center will be sustained down the line in part through research grants, subcontracting work, and perhaps foundation support.

"We’ll see if we cannot make this viable," he said. "Over time, we suspect we will get some intellectual property, but intellectual property is not the lifeblood."

SLU has already started writing up an application for a federal stimulus-funded research grant at the new center, he said.

Down the line, Tait said, SLU could work with pharmaceutical companies — including, but not limited to, Pfizer.

"I don’t see us undertaking clinical trials," he said. "What I can see us doing is identifying some promising treatment approaches, working to where we have some evidence or sense that they are safe. But in order to bring them to market, we will have to partner."

Source

Save up to $500 on your auto insurance! Compare car insurance rates, or get an insurance quote online.

Homeowners seeking relief under the Obama administration’s mortgage aid program will be required to provide proof of their incomes upfront, a significant reversal for the problem-plagued effort to stem the foreclosure crisis.

Borrowers had been able to state their income verbally and provide documentation later. Mortgage companies, however, said many borrowers didn’t return the documents.

Only about 66,500 borrowers, or 7 percent of those who signed up, had completed it as of December.

Lenders will now be required to collect two recent pay stubs at the start of the process, the Treasury Department said Thursday. Borrowers will have to give the IRS permission to provide their most recent tax returns, rather than submitting the returns themselves.

The changes become mandatory for loan modifications made starting June 1.

The change in policy came after officials concluded that mortgage companies such as GMAC Mortgage and Ocwen Financial Corp. were delivering better results. They had always required documents up front.

Under the new rules, participating mortgage companies must acknowledge receipt of a borrower’s application within 10 days and approve or deny the application within 30 days. After that, borrowers will still be required to make three months of trial payments before the modification becomes permanent.

While the changes should help, the lack of penalties for companies who don’t comply disappointed some experts. "There’s no teeth to that obligation," said Andrew Jakabovics, associate director for housing at the Center for American Progress, a liberal think tank.

Many consumer groups, meanwhile, have been calling for more dramatic changes. They want to help homeowners who have lost their jobs and those who owe the bank more than their homes are worth.

Treasury officials said they are studying ways to aid unemployed homeowners but offered no details.

Source

U.S. venture investment activity in 2009 was as low as its been since 1997, according to a report from the National Venture Capital Association and PricewaterhouseCoopers.

The $17.7 billion invested was down 37 percent from 2008 and the 2,795 deals was down by 30 percent.

There was $6.98 billion invested in Silicon Valley companies, about 40 percent of the U.S. total, down from $10.7 billion in 2008. That is the lowest valley total since the end of the tech bust in 2003 when only $6.4 billion was invested.

The number of deals in the Bay Area dropped to 863 from 1,232 in 2008.

By sector, the report said:

— Biotechnology investing declined in 2009 by 19 percent in both dollars and deals, but was the largest investment sector for the year in terms of dollars with $3.5 billion going into 406 deals.

— The medical device sector fell 27 percent in dollars and 19 percent in deals in 2009, finishing the year as the third largest sector with $2.5 billion going into 309 deals.

— The life sciences sector (biotech and medical devices combined) accounted for 34 percent of all venture capital dollars invested in 2009 compared to 28 percent in 2008 fast cash advance.

— In the software sector, venture capitalists invested $3.1 billion into 619 deals, a 40 percent decline in dollars and a 35 percent decline in deals from 2008. Software was the largest single industry category in terms of deal volume and second largest behind biotechnology in terms of dollars.

— Clean technology investing saw a significant decline in 2009 with $1.9 billion invested in 185 deals. This is a 52 percent decrease in dollars and a 31 percent decline in deal volume from 2008.

— Investing in Internet-specific companies dropped 39 percent to $2.9 billion. There were 629 deals in 2009, down 30 percent.

The industries with the biggest declines were telecommunications (down 67 percent); semiconductors (down 53 percent); and industrial/energy (down 50 percent). The media and entertainment industry decreased 32 percent in terms of dollars and 38 percent in terms of deals with $1.2 billion going into 251 deals in 2009.

Source

European finance chiefs said Greece may have to step up its efforts to tackle a national fiscal crisis that threatens to spread to other countries across the region.

“The Greek government is aware of the magnitude of the problems facing the country,” Luxembourg’s Jean-Claude Juncker told reporters in Brussels late yesterday after leading a meeting of euro-area finance ministers that discussed Greece’s budget plan. “The measures are a step in the right direction. We’ll have to see whether they’re enough.”

Greece last week presented its plan to push down a budget deficit that is still more than four times the European Union limit of 3 percent of gross domestic product. European Central Bank President Jean-Claude Trichet on Jan. 14 turned up the pressure on Greece, saying no nation can expect any “special treatment” after rating downgrades sparked a rout in Greece’s bonds in December and fueled concerns about default.

The Greek government’s latest proposals call for about 10 billion euros ($14.4 billion) of spending cuts and revenue increases this year to bring the budget shortfall from 12.7 percent of output to 8.7 percent by year end.

“The Greek plan leans heavily on the income side,” Dutch Finance Minister Wouter Bos said after yesterday’s meeting. “It leans heavily on one-time measures,” he said, adding that the program “needs to be more substantial.”

More-Reliable Statistics

The government in Athens presented a “very ambitious” budget-cutting program, Greek Finance Minister George Papaconstantinou told reporters yesterday. Greek officials also pledged to provide more-reliable statistics after the EU said earlier this month that the country’s data contained “severe irregularities.”

While the Greek government still has “difficult work to do,” German Finance Minister Wolfgang Schaeuble said the “serious reforms made to their statistics will help detect and avoid more problems like this in the future.” Bos said a “strong exercise” is required to make Greek data “reliable again.”

Juncker, who serves as Luxembourg’s premier and treasury minister, won a new term as head of the so-called eurogroup at yesterday’s meeting. He was unanimously appointed to a fresh term of two and half years under the Lisbon Treaty, which came into force in December.

The finance chiefs delayed until next month a decision on who will succeed Lucas Papademos as vice president of the European Central Bank, Juncker said. Luxembourg central bank chief Yves Mersch, his Portuguese counterpart Vitor Constancio and ECB Banking Supervision Committee Chairman Peter Praet are the three candidates being considered for the post.

Source

DETROIT–The race to build alternative energy vehicles moved up a notch Monday when Toyota Motor Corp. revealed a hybrid compact for the first time that could move into production within three to five years.

In unveiling a lime green FT-CH "dedicated hybrid," at the less splashy than usual North American International Auto Show, Toyota revealed it also plans to boost its gas-electric fleet with eight new models during the next few years – and none of them will be next-generation versions of current vehicles. The company now has seven hybrids in showrooms.

Toyota, which surpassed General Motors as the auto industry’s world leader last year, said it plans to hit one million in annual worldwide hybrid sales early this decade. Most of those sales will come in North America, where consumers, because of climbing gas prices and climate-change concerns, are starting to shift to smaller, fuel-efficient vehicles that are less damaging to the environment.

Toyota officials said the Japanese automaker’s assault on the alternative energy car market will include the development of a family of vehicles around the Prius, the company’s flagship hybrid model. The Prius, the world’s first hybrid, reached sales of more than two million during the past decade.

Ray Tanguay, a managing officer for parent Toyota and chief executive officer of the company’s Canadian manufacturing operations, said the FT-CH is under consideration for production in Japan in the three- to five-year range.

"It’s a fair expectation," he said.

Tanguay said Toyota is targeting young buyers, or what some company officials call the "8-bit generation," after the microprocessor technology that dominated the budding home video game industry during the 1980s. Pricing would be below the Prius, which now has a base manufacturer’s suggested retail price of about $27,000.

Toyota said the vehicle is lighter and more fuel efficient than the Prius. It is 22 inches shorter than the mid-size Prius but can still seat five people comfortably, the company noted in promotional material.

Prius sales improved marginally in Canada last year to 4,610 despite a sharp decline in the overall market.

Toyota, which struggled like other major automakers because of the world recession last year, wants to offer a variety of hybrid choices, including plug-in models by 2012 and hydrogen fuel cell vehicles in 2015.

"We must re-imagine the automobile, a century after its invention, with powertrains that greatly reduce or even eliminate the use of conventional petroleum fuels," said Toyota Canada president Yoichi Tomihara. "The electrification of the automobile is just one of many alternatives and the most successful example of this to date has been the gas-electric hybrid."

However, Toyota and other automakers have acknowledged they face major a challenge to reduce the cost of hybrids and full electric vehicles to make them more affordable and practical to consumers because of battery costs, travel range and charging infrastructure.

Some other automakers promoted their hybrid and electric capabilities at the show. Fiat, Chrysler’s new partner, showed an electric Fiat 500 subcompact, for example, but the company did not disclose any timing for production.

The 22nd annual show’s media preview did not feature the splashy presentations that dominated the event in the past. Instead, companies showed smaller vehicles with an emphasis on fuel economy.

More politicians toured the event since the U.S. and Canadian governments have become shareholders in GM and Chrysler, which got taxpayer loans to stay alive last year.

"It’s not an auto show any more," said veteran industry watcher Dennis DesRosiers. "It’s a political spin show … the industry has to show governments they’re listening."

He said in the U.S., several automakers are working on costly technology to improve fuel economy without downsizing autos because Americans won’t buy enough smaller vehicles.

"The question is will there be enough volume because of the higher prices," he said. "It may take a decade before those prices come down enough."

Source

Tiger Woods’ much-publicized marital problems have started to cost him money. But they’re probably going to hurt the pro golf tour, and its various sponsors and broadcasters, even more.

At the very least, Woods could lose significant earnings from the tour. In 2009, he was the sport’s top money winner with purses totaling $10.5 million.

Sports marketing consultant Marc Ganis said that Woods’ estimated $1 billion in lifetime earnings on and off the course mean his finances are completely secure, even if he has to pay a large divorce settlement. He said the bigger hit could be for the rest of his sport.

"The golf industry needs Woods far more today than he needs the golf industry," said Ganis.

The PGA Tour issued its own statement Friday saying it supported Woods’ decision to take a leave. "We look forward to Tiger’s return to the PGA Tour when he determines the time is right for him," the statement said.

Ty Votaw, executive vice president of the PGA Tour, said the tour couldn’t speculate on the economic impact of Woods’ absence because the length of his leave isn’t known yet.

He said final financial figures from the 2009 season are not yet available, but that they will show a decrease from the record $124 million the tour donated to charities in 2008, a close approximation of the tour’s profit. He attributed the decline to the recession.

David Carter, executive director of the Sports Business Institute at the University of Southern California, said losing Woods comes at a bad time for the PGA, given the bite the recession has put on sponsorships.

"The PGA is just now fully appreciating what the financial fallout may be," he said. "Its fallout may last for years."

Viewership for golf tournaments is likely to plunge as long as he stays off the tour. A study by rating firm Nielsen a year ago, when Woods was returning from a six-month injury rehabilitation, found that ratings for tournaments he missed in 2008 after playing them in 2007 were down an average of 47%.

Even the major tournaments are likely to take a hit in their television audience if he misses them. Nielsen found that viewership for the final day of the Masters fell 20% in the years that Woods did not win the most watched tournament.

Neal Pilson, a sports broadcasting consultant who used to run CBS Sports, said the market for ads on this year’s tournaments was soft even before Woods’ problems burst into view. "Now everyone is in a wait-and- see mode," he said.

Most of the tournaments have multi-year contract deals, but networks might need to offer additional ad time to advertisers if the ratings plunge as much as feared, said Pilson. But he said the market won’t collapse altogether, given the fact that the average golf viewer is more affluent than the fans of many other sports.

"We did sell golf before Tiger showed up. But just as there was a Michael Jordan bubble when he was winning championships with the Bulls, there has been a Tiger bubble in golf ratings," he said.

But Ganis said even after Woods returns networks might be less willing to sign new deals for the second-tier tournaments due to losses they might suffer during his absence.

But television deals are only part of the revenue stream for the PGA. It also depends heavily on sponsorship dollars cash till payday. He said Woods’ problems give sponsors one more reason to question the money they’ll spend on golf tournaments.

"They have to try to calibrate what their spending will be in the sport at a time when marketing budgets are very hard to justify," said Carter.

While some tournaments have gone out of business in the last two years, they have generally been replaced by new tournaments, including one which Woods himself hosts along with AT&T (T, Fortune 500), one of his sponsors.

Woods’ sponsors pull back

But the tour isn’t the only one that could lose sponsors. The bad publicity about his admitted infidelity could also cost Woods some of his own sponsorship deals down the road.

The first golf shoe to drop came Sunday when business consultant Accenture, which had previously made Woods the focus of its marketing campaign, announced it would no longer use him because "the company has determined that he is no longer the right representative for its advertising."

But Accenture did not respond to questions about whether it would have to continue to pay Woods under terms of his contract. Experts in the field say that while sponsors are likely to keep their Tiger Woods commercials off the air while he takes his leave from the game, most will continue to pay him the millions owed under those contracts.

The loss of sponsorship money in the future is inevitable given the damage done to the Woods image in the last couple of weeks.

"He probably won’t have to take less from the sponsors he keeps," said Ganis. "He’s made a lot of money for those guys. But he’ll probably have fewer sponsors in the future as these deals come up for renewal."

He said he thinks the deals with AT&T (T, Fortune 500), PepsiCo’s (PEP, Fortune 500) Gatorade brand and Procter & Gamble’s (PG, Fortune 500) Gillette are the deals most at risk. AT&T issued a statement over the weekend that it is "presently evaluating our ongoing relationship with him."

But Ganis said Woods is certain to keep at least a couple of his top sponsorship deals — including his biggest at Nike (NKE, Fortune 500), reported to be worth $40 million.

"There was no Nike Golf before Tiger. Nike’s not going anywhere," he said. "Neither is (video game maker) Electronic Arts."

Nike issued a statement saying that Woods and his family has "Nike’s full support," and that it looks forward to his return to playing. Nike Golf suffered a $77 million, or 11%, revenue decline in the fiscal year ended May 31, which it attributed to the recession cutting into discretionary spending, even as the company’s overall revenue rose 3%.

EA (ERTS) also issued a statement supporting Woods Friday, stating "At this time, the strategy for our Tiger Woods PGA Tour business remains unchanged."

Gillette’s statement over the weekend did not speak of its long-term plans for its deal with Woods, saying only "As Tiger takes a break from the public eye, we will support his desire for privacy by limiting his role in our marketing programs."

Gatorade did not respond to requests for comments Monday. 

Source

NEW YORK–A nine-month rally in oil prices could be faltering as a gradual sell-off that began in late October gains momentum.

Crude prices, which doubled from March to October, slipped Friday for the eighth day in a row. The January contract fell 67 cents to settle at $69.87 (U.S.) a barrel on the New York Mercantile Exchange. It’s the first time oil has settled below $70 a barrel since early October.

Prices hit two-month lows as the greenback gained strength and investors took a second look at paltry demand figures in the West.

All energy prices were in retreat despite a report Friday from the International Energy Agency saying global oil demand will rise more than previously expected next year payday loans. Analysts said they’ve heard such talk before, and they’re now looking for concrete signs of demand from both consumers and industry.

The IEA, an energy watchdog for some of the biggest oil consuming nations, said it was raising its estimates for 2010 global oil demand because of increased economic activity in Asia and the Middle East.

Associated Press

Source

One year since the arrest of Ponzi mastermind Bernard Madoff, most of his victims are still trying to recoup their losses.

"We’ve got nothing back," said Dana Foy, a 57-year-old computer programmer in New Mexico.

Foy, who wouldn’t identify how much money he lost, saw his dream of a comfortable retirement with his wife wiped out by Madoff’s scheme, which came crashing down when he was arrested on Dec. 11, 2008.

About $20 billion in investor funds were lost to Madoff’s scam, according to the Web site of the court-appointed trustee Irving Picard, who is tasked with recovering and allocating as much of the money as possible. Some of the victims have been reimbursed, but many are still waiting.

Of the 16,000 claims that have been filed, about 70% have been processed, according to Picard. Of those 11,563 processed claims, 1,647 have been determined to be valid. Most of the claims, some 9,916, have been denied.

Most of the denied claims are "indirect" investors who did not have an account at Madoff’s firm, according to Stephen Harbeck, chief executive of the Securities Investor Protection Corporation. Indirect investors include those in feeder funds, which are other funds that place their money with Madoff. Claimants have to try and get reimbursement from those fund managers, not through the trustee.

The SIPC has allocated $561.3 million to the 1,647 approved claims. Some of those claims have been paid out and some have not. But that still falls short of the $4.69 billion the trustee has earmarked for victim compensation - much of which would come from the sale of Madoff’s assets.

The trustee has not yet sent out money from confiscated assets, which it is still in the process of recovering.

"We don’t understand why it’s taken so long," said Ilene Kent, coordinator with Investor Action Group, which was organized for Madoff victims like herself.

In an e-mail to CNNMoney.com, Harbeck identified the various factors that can affect "the reconstruction of a claim," including "the length of time a customer had an account, coupled with multiple withdrawals in addition to deposits and the completeness of the paperwork submitted by the customer."

The SIPC covers up to $500,000 per account for victims who’ve lost money. That includes Korean War veteran Allan Goldstein, 77, who said he had invested $2 million with Madoff’s firm.

His final statement from Madoff said his investments had grown to $4.7 million. Goldstein had also drawn down about $300,000 annually to live on for a number of years.

Goldstein said the trustee subtracted the withdrawals from his $2 million investment, resulting in the $320,000 he received from SIPC. He and his wife used that money to buy a house in Great Barrington, Mass. Because of his withdrawals, Goldstein is not expecting to receive money from Madoff’s confiscated assets.

Ponzi schemers operate by masquerading as legitimate money managers. Madoff didn’t invest his clients’ money — he stole it no faxing payday loan. He kept the scam going for years by allowing some of his clients to withdraw money, while fraudulently portraying those withdrawals as legitimate returns.

Goldstein said that he and his wife currently live on Social Security and assistance from their children. That’s a stark contrast from the affluent retirement that he’d planned.

"The whole thing is a nightmare," he said. "We do the best we can, and we’re surviving. We’re very happy, at least, to be living in our own home."

Madoff’s money trail

Any losses beyond SIPC are set to be recouped through the recovery of stolen assets, such as Madoff’s yacht and his multi-million dollar properties in Manhattan, Montauk, N.Y., Palm Beach, Fla. and Cap d’Antibes on the French coast.

Maureen Ebel, 61, of West Chester, Pa., said she invested $5.3 million in Madoff’s firm through two separate accounts, and the latest statement from the firm said her investments had grown to $7.3 million. She recovered $1 million from SIPC — $500,000 for each of her two accounts — but she’s still missing millions.

"I don’t think I’ll ever see any of it, quite frankly," said Ebel. "We don’t even know where it is."

So far, investigators say they have confiscated about $1.5 billion worth of assets from Madoff’s estate, which falls far short of the approximately $20 billion in investor funds that were lost to his scheme.

The recovery process continues. Picard has filed 14 lawsuits against Madoff’s friends and family.

Investigators have no idea how long it will take to track down the stolen money and have not set a deadline for discontinuing the recovery, according to the trustee’s office.

Madoff’s trail of victims

Meanwhile, Madoff languishes in prison. He pleaded guilty in March to 11 counts related to running his Ponzi scheme and was sentenced to 150 years. Madoff, 71, is incarcerated at the Federal Correctional Institution Butner in North Carolina and faces an official release date of Nov. 14, 2139.

But this provides little comfort to some of this victims.

"He’s away, he can’t hurt anyone else, and that’s a good thing," said Mike De Vita, a computer programmer from Philadelphia who lost 40 years worth of retirement savings to Madoff’s scam. "But other than that, what happens to Bernard Madoff doesn’t really matter."

Ebel, who ditched her plans for a comfortable retirement and reentered the workforce as an office manager, resents Madoff for wiping out the savings that her late husband had left her.

"[Madoff] has ruined so many lives and caused so much pain to so many people that he will never get what he deserves until he dies," she said. "May God have mercy on him." 

Source

U.K. house prices will rise in the next year, according to a majority of consumers in a survey last month by Rightmove Plc.

Fifty-four percent of respondents expect average house prices to be higher in 12 months, the U.K.’s biggest property Web site said in an e-mailed statement today in London. In the first quarter, more than 68 percent of consumers polled forecast lower prices in a year’s time.

House prices are rebounding from a rout that shaved about 20 percent off average values as demand for new property outstrips supply. Bank of England policy makers said this month that the outlook for the housing market’s recovery depends on the availability of mortgage finance.

“Those surveyed may feel that prices will increase, but that does not necessarily mean that they are willing or able to purchase themselves, especially given the tight lending criteria required to access the best rates,” Miles Shipside, commercial director of Rightmove, said in the statement loans until payday.

The Bank of England said last week the outlook for the housing market “will depend, in part, on the supply of mortgage credit.” While U.K. mortgage approvals climbed to their highest level for 18 months in September, they’re still only half what they were when the credit crisis started in September 2007.

Prices rose for a third month in October after they had dropped as much as a fifth from 2007, Hometrack Ltd. said earlier this month.

Rightmove said more than 68 percent of respondents described now as a good time to buy while 5 percent said it was a good time to sell. The poll of 34,056 people was conducted from Oct. 5 to Oct. 19.

Source